Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07449052

Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease

The goal of this clinical trial is to test whether adding coronary function testing and starting targeted medical treatment for identified vasomotor disorders will also improve angina symptoms and quality of life in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention. The main question it aims to answer is:

Does performing coronary function testing in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention lead to better relieve of angina symptoms and improvement in quality of life?

Researchers will compare this group undergoing coronary function testing with a control group who will solely undergo percutaneous coronary intervention.

Participants will:

* Undergo percutaneous coronary intervention and coronary function testing in the intervention arm * Undergo percutaneous coronary intervention in the control arm

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >18 years of age
  • Hemodynamically relevant obstructive coronary artery disease (as assessed by pressure wire evaluation) in the left anterior descending coronary artery amenable to percutaneous coronary intervention at the discretion of the operator.

Exclusion criteria

  • Prior coronary artery bypass graft surgery.
  • Stenosis >90% in the target vessel or a stenosis deemed unsafe for pressure wire instrumentation
  • Known severe left ventricular dysfunction (left ventricular ejection fraction by any imaging modality)
  • Severe valvular disease
  • Renal impairment (estimated glomerular filtration rate <30mL/min)
  • Contra-indications for the use of adenosine or acetylcholine
  • Expected inability to conform to the clinical follow-up
  • Unable or unwilling to use the ORBITA-app
  • Life expectancy of less than 12 months.

Treatment and study plan

Coronary function testing

Diagnostic Test

Coronary function testing to test for coronary microvascular dysfunction and coronary vasospasm

Other names: CFT

Percutaneous coronary intervention

Procedure

Percutaneous coronary intervention performed according to local practice standards and guidelines

Other names: PCI

Primary outcomes

  1. Angina symptom burden

    Time frame: From baseline to 6 months of follow-up (after procedure)

    The difference in the change in angina symptom score between groups from baseline to 6-month follow-up. Patients will keep track of their symptoms daily during which they can answer the question if they had symptoms with 'yes' or 'no'. If 'yes' is selected, they can select how frequent their attacks were on that day (from 0-10, were 0 = no attack and 10 = 10 or more attacks) and also the severity of the attacks (mild, moderate or severe). A higher score means a worse outcome.

Secondary outcomes

  1. Difference Seattle Angina Questionnaire Summary Score (SAQSS)

    Time frame: From baseline to 6 months of follow-up (after procedure)

    The mean difference in the within-subject change in Seattle Angina Questionnaire Summary Score (SAQSS) between the groups from baseline to 6-month follow-up. The score ranges from 0-100, where a higher score means a better outcome.

  2. Difference Canadian Cardiovascular Society (CCS) grading of angina pectoris

    Time frame: From baseline to 6 months of follow-up (after procedure)

    Between-group difference in angina severity as assessed by the Canadian Cardiovascular Society class at 6-month follow-up and its change from baseline to 6-month follow-up. There are four classes: I, II, III and IV. A higher class means a higher angina/symptom burden (worse outcome).

  3. Difference Seattle Angina Questionnaire (SAQ)

    Time frame: From baseline to 6 months of follow-up (after procedure)

    Between-group difference in physical limitation, angina stability, quality of life, angina frequency, freedom from angina as assessed with the Seattle Angina Questionnaire (SAQ) at 6-month follow-up, and their change from baseline to 6-month follow-up. The subscales are all transformed to a scale from 0-100, where a higher score means a better outcome.

  4. Difference EuroQol-5 Dimension-5 Level Questionnaire (EQ-5D-5L)

    Time frame: From baseline to 6 months of follow-up (after procedure)

    Between-group difference in quality of life as assessed with the EQ-5D-5L quality of life questionnaire at 6-month follow-up, and their change from baseline to 6-month follow-up. There are 5 domains with 5 levels, in which the scores are transformed to values ranging from -0,109 to 1,000. The EQ-5D-5L Visual Analog Scale (VAS) score, as part of the questionnaire, ranges from 0-100. In both cases a higher score means a better outcome.

  5. Difference Patient Global Impression of Change (PGI-C)

    Time frame: At 6 and 12 months of follow-up (after procedure)

    Patient Global Impression of Change (PGI-C) Score: at 6-, and 12-months post-procedure. The score ranges from 1-7, where a lower score means (better) improvement and higher scores means no improvement/worsening (worse outcome).

  6. Prevalence coronary vasomotor disorders

    Time frame: From baseline to 12 months of follow-up (after procedure)

    Prevalence of individual coronary vasomotor disorder endotypes in the intervention arm.

  7. Disease endotype

    Time frame: From baseline to 12 months of follow-up (after procedure)

    Impact of disease endotype on the between-group difference in clinical response to percutaneous coronary intervention.

  8. Role coronary computed tomography angiography (CCTA)

    Time frame: From baseline to 12 months of follow-up (after procedure)

    Relationship of coronary computed tomography angiography (CCTA) parameters (collected from patients from whom images are available) with hemodynamic relevance of coronary stenosis and the presence of coronary vasomotor disorders.

  9. Role of biomarkers

    Time frame: From baseline to 12 months of follow-up (after procedure)

    Relationship of biomarker levels and the presence of coronary vasomotor dysfunction.

  10. Adverse events

    Time frame: From baseline to 12 months of follow-up (after procedure)

    Adverse clinical events: Hospital admission for angina pectoris, acute coronary syndrome, unscheduled (repeat) coronary angiography, (cardiac) death.

  11. Similarity score

    Time frame: From baseline to 12 months of follow-up (after procedure)

    Placebo controlled similarity score during low pressure balloon occlusion of the coronary artery, and during coronary function testing in the CFT-guided (intervention) arm, and its relationship with change in angina symptom score after revascularization. The similarity score ranges from 0-10, where 0 means patient has no (recognizable) complaints and 10 means patient experiences exactly the same pain as usual.

  12. Difference MacNew score

    Time frame: From baseline to 6 months of follow-up (after procedure)

    Between-group difference in quality of life as assessed with the MacNew quality of life questionnaire at 6-month follow-up. There are several items, which are scored from 1-7. Domain scores and global scores are calculated using the average scores of these items (so also from 1-7). A higher score means a better outcome.

  13. Canadian Cardiovascular Society (CCS) grading of angina pectoris at 12 months

    Time frame: From baseline to 12 months and from 6 months to 12 months of follow-up (after procedure)

    Change in CCS class from 6-months to 12-months and from baseline to 12-months. There are four classes: I, II, III and IV. A higher class means a higher angina/symptom burden (worse outcome).

  14. Seattle Angina Questionnaire (SAQ) at 12 months

    Time frame: From baseline to 12 months and from 6 months to 12 months of follow-up (after procedure)

    Change in SAQ from 6-months to 12-months and from baseline to 12-months. The subscales are all transformed to a scale from 0-100, where a higher score means a better outcome.

  15. Seattle Angina Questtionaire Summary Score (SAQSS) at 12 months

    Time frame: From baseline to 12 months and from 6 months to 12 months of follow-up (after procedure)

    Change in SAQSS from 6-months to 12-months and from baseline to 12-months. The score ranges from 0-100, where a higher score means a better outcome.

  16. EuroQol-5 Dimension-5 Level Questionnaire (EQ-5D-5L) at 12 months

    Time frame: From baseline to 12 months and from 6 months to 12 months of follow-up (after procedure)

    Change in EQ-5D-5L from 6-months to 12-months and from baseline to 12-months. There are 5 domains with 5 levels, in which the scores are transformed to values ranging from -0,109 to 1,000. The EQ-5D-5L Visual Analog Scale (VAS) score, as part of the questionnaire, ranges from 0-100. In both cases a higher score means a better outcome.

  17. MacNew at 12 months

    Time frame: From baseline to 12 months and from 6 months to 12 months of follow-up (after procedure)

    Change in MacNew from 6-months to 12-months and from baseline to 12-months. There are several items, which are scored from 1-7. Domain scores and global scores are calculated using the average scores of these items (so also from 1-7). A higher score means a better outcome.

Sponsors and collaborators

Lead sponsor

UMC Utrecht

Other

Registry information

Official study title

Inclusive Invasive Physiological Assessment in Angina Syndromes - Obstructive Coronary Artery Disease

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Mar 4, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.